Hideaki Suzuki, Takumi Inoue, Yousuke Terui, Kouki Takeuchi, Kai Susukita, Marina Arai, Haruka Sato, Taijyu Satoh, Saori Yamamoto, Nobuhiro Yaoita, Shunsuke Tatebe, Hideka Hayashi, Kotaro Nochioka, Hiroyuki Takahama, Satoshi Yasuda
AIMS: Vericiguat has been used to treat patients with heart failure with reduced ejection fraction (HFrEF) who demonstrated worsening heart failure despite treatment with other guideline-directed medical therapies. The haemodynamic effects of vericiguat remain unclear. METHODS AND RESULTS: This study enrolled 12 patients (median age, 63 [quartiles 53.5, 70] years; 16.7%(N=2) women) with symptomatic HFrEF (New York Heart Association functional class II-IV) who demonstrated worsening heart failure despite treatment with the four foundational guideline-recommended therapies between March and December 2022, with follow-ups completed in June 2023...
April 29, 2024: ESC Heart Failure